Evidence map›Paper›PMID 31749211›Full record

ArticleJournal of clinical laboratory analysis2020

Molecular, biochemical, and clinical analyses of five patients with carbamoyl phosphate synthetase 1 deficiency.

Lijuan Fan, Jing Zhao, Li Jiang, Lingling Xie, Jiannan Ma, Xiujuan Li, Min Cheng

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lijuan FanDepartment of Neurology, Children's Hospital of Chongqing Medical University, Chongqing, China.
Jing ZhaoMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Li JiangDepartment of Neurology, Children's Hospital of Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0000-0002-9793-6846
Lingling XieDepartment of Neurology, Children's Hospital of Chongqing Medical University, Chongqing, China.
Jiannan MaDepartment of Neurology, Children's Hospital of Chongqing Medical University, Chongqing, China.
Xiujuan LiDepartment of Neurology, Children's Hospital of Chongqing Medical University, Chongqing, China.
Min ChengDepartment of Neurology, Children's Hospital of Chongqing Medical University, Chongqing, China.
China International Science and Technology Cooperation · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCarbamoyl phosphate synthetase 1 deficiency (CPS1D) is a rare urea cycle disorder. The aim of this study was to present the clinical findings, management, biochemical data, molecular genetic analysis, and short-term prognosis of five children with CPS1D.

methodsThe information of five CPS1D patients was retrospectively studied. We used targeted next-generation sequencing to identify carbamoyl phosphate synthetase 1 (CPS1) variants in patients suspected to have CPS1D. Candidate mutations were validated by Sanger sequencing. In silico and structure analyses were processed for the pathogenicity predictions of the identified mutations.

resultsThe patients had typically clinical manifestations and biochemical data of CPS1D. Genetic analysis revealed nine mutations in the CPS1 gene, including recurrence of c.1145C > T, five of which were firstly reported. Seven mutations were missense changes, while the remaining two were predicted to create premature stop codons. In silico and structure analyses showed that these genetic lesions were predicted to affect the function or stability of the enzyme.

conclusionWe reported five cases of CPS1D. Five novel mutations of CPS1 gene were found. Mutations of CPS1 have private nature, and most of them are missense compound heterozygous. The mutation affecting residue predicted to interfere the catalytic sites, the internal tunnel, or the regulatory domain results in severe phenotype.

Indexed as

MutationCarbamoyl-Phosphate Synthase (Ammonia)Carbamoyl-Phosphate Synthase I Deficiency DiseaseChildChild, PreschoolFemaleHumansInfantInfant, NewbornMaleCarbamoyl-Phosphate Synthase (Ammonia)CPS1 protein, humancarbamoyl phosphate synthetase 1 deficiencyclinical presentationCPS1hyperammonemiaurea cycle disorders

Identifiers

PMID31749211
PMCPMC7171324
OpenAlexW2991634387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.